Arcus Biosciences Inc (NYSE:RCUS) has been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price objective of $21.50 for the company and are expecting that the company will post ($0.38) EPS for the current quarter, according to Zacks. Zacks has also assigned Arcus Biosciences an industry rank of 101 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, June 15th.
Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Monday, August 6th. The company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.08. The business had revenue of $1.25 million during the quarter, compared to analyst estimates of $1.30 million. research analysts anticipate that Arcus Biosciences will post -1.81 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in RCUS. Wells Fargo & Company MN acquired a new stake in Arcus Biosciences in the first quarter worth about $155,000. Dean Capital Investments Management LLC acquired a new stake in Arcus Biosciences in the first quarter worth about $303,000. BVF Inc. IL acquired a new stake in Arcus Biosciences in the first quarter worth about $19,606,000. BlackRock Inc. acquired a new stake in Arcus Biosciences in the first quarter worth about $303,000. Finally, Artal Group S.A. acquired a new stake in Arcus Biosciences in the first quarter worth about $4,632,000. Hedge funds and other institutional investors own 33.23% of the company’s stock.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.
See Also: What is the NASDAQ Stock Market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.